Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and Satellites
A Q&A session with the expert panel.
Unmet Needs in the Treatment of Multiple Myeloma
The panel highlights remaining unmet needs in the management of multiple myeloma and speculates on the future of treatment.
Comparing Bispecifics and CAR T-Cell Therapy for Patients With MM
Noffar Bar, MD, shares how she would choose between the potential bispecific antibodies for treatment of multiple myeloma after recent data updates.
Discussing Bispecific Antibody Treatment With Patients With Multiple Myeloma
Catherine Wei, MD, and David Witt, MD, explain some of the reasons they would recommend treatment with bispecific antibodies to their patients with multiple myeloma.
Application of Bispecific Therapy in Clinical Practice
Syed S. Ali, MD, and Noffar Bar, MD, share their practical experience with bispecific antibodies in the treatment of patients with multiple myeloma.
Updated Results of the MonumenTAL-1 Study in R/R MM
Noffar Bar, MD, details data on talquetamab in R/R MM treatment from the MonumenTAL-1 study, and Syed S. Ali, MD, speaks to his experience with teclistamab in clinical practice.
Available Treatment Options for Patients With R/R MM
Elan Gorshein, DO, JD, MPH, explains his choice of frontline therapy for patients with relapsed/refractory multiple myeloma.
Subset Analysis of the MAIA Study in the Frail Multiple Myeloma Population
Experts comment on the subset analysis of the MAIA study in the frail NDMM patient population.
Treatment Approaches in Patients With Transplant-Ineligible NDMM
Noffar Bar, MD, discusses the MAIA study investigating a daratumumab combination therapy in patients with transplant-ineligible multiple myeloma.
Assessing and Treating Patients with High-Risk NDMM
Elan Gorshein, DO, JD, MPH, describes potential approaches to managing high-risk patients with transplant-eligible NDMM.
Exploring the GMMG-CONCEPT Study in Patients With Transplant-Eligible NDMM
Noffar Bar, MD, explains the GMMG-CONCEPT trial in patients with transplant-eligible NDMM.
Data Updates From GRIFFIN and MASTER in Transplant-Eligible NDMM
David Witt, MD, details the design and outcomes of the GRIFFIN study in newly diagnosed multiple myeloma.
Triplet and Quadruplet Induction Regimen Options for Patients With Transplant-Eligible NDMM
Natalia Neparidze, MD, reviews the available induction treatment options for patients with newly diagnosed multiple myeloma (NDMM).